Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Comparison of algorithms for the detection of cancer drivers at subgene resolution

  • Porta-Pardo, Eduard
  • Kamburov, Atanas
  • Tamborero Noguera, David
  • Pons, Tirso
  • Grases, Daniela
  • Valencia, Alfonso
  • López Bigas, Núria
  • Getz, Gad
  • Godzik, Adam
Understanding genetic events that lead to cancer initiation and progression remains one of the biggest challenges in cancer biology. Traditionally, most algorithms for cancer-driver identification look for genes that have more mutations than expected from the average background mutation rate. However, there is now a wide variety of methods that look for nonrandom distribution of mutations within proteins as a signal for the driving role of mutations in cancer. Here we classify and review such subgene-resolution algorithms, compare their findings on four distinct cancer data sets from The Cancer Genome Atlas and discuss how predictions from these algorithms can be interpreted in the emerging paradigms that challenge the simple dichotomy between driver and passenger genes., E.P.-P. and A.G. acknowledge the support from the Cancer Center grants P30 CA030199 (to our institute) and R35 GM118187 (A.G.). A.K. was supported by startup funds of G.G. and by a collaboration with Bayer AG. D.T. is supported by project SAF2015-74072-JIN, which is funded by the Agencia Estatal de Investigacion (AEI) and Fondo Europeo de Desarrollo Regional (FEDER). N.L.-B. acknowledges funding from the European Research Council (consolidator grant 682398). A.V. and T.P. acknowledge funding by the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 305444 (RD-Connect)
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations

  • Tamborero Noguera, David
  • Rubio Pérez, Carlota, 1990-
  • Déu Pons, Jordi
  • Schroeder, Michael Philipp, 1986-
  • Vivancos Prellezo, Ana
  • Rovira Guerín, Ana
  • Tusquets Trias de Bes, Ignacio
  • Albanell Mestres, Joan
  • Rodon, Jordi
  • Tabernero Cartula, Josep
  • Torres, Carmen de
  • Dienstmann, Rodrigo
  • González-Pérez, Abel
  • López Bigas, Núria
While tumor genome sequencing has become widely available in clinical and research settings, the interpretation of tumor somatic variants remains an important bottleneck. Here we present the Cancer Genome Interpreter, a versatile platform that automates the interpretation of newly sequenced cancer genomes, annotating the potential of alterations detected in tumors to act as drivers and their possible effect on treatment response. The results are organized in different levels of evidence according to current knowledge, which we envision can support a broad range of oncology use cases. The resource is publicly available at http://www.cancergenomeinterpreter.org., This project has received funding from Fundació La Marató de TV3, the European Union's Horizon 2020 research and innovation programme 2014-2020 under grant agreement number 634143, and by the European Research Council (Consolidator Grant 682398). IRB Barcelona is a recipient of a Severo Ochoa Centre of Excellence Award from the Spanish Ministry of Economy and Competitiveness (MINECO; Government of Spain) and is supported by CERCA (Generalitat de Catalunya). DT is supported by project SAF2015-74072-JIN funded by the Agencia Estatal de Investigacion (AEI) and Fondo Europeo de Desarrollo Regional (FEDER). CR-P is funded by a FPI MINECO grant (BES-2013-063354). AG-P is supported by a Ramon y Cajal fellowship (RYC-2013-14554).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets

  • Karube, Kennosuke
  • Rubio Pérez, Carlota, 1990-
  • Tamborero Noguera, David
  • Salar, Antonio
  • Colomo Saperas, Luis Alberto
  • López Bigas, Núria
  • Miyoshi, Hiroaki
Genome studies of diffuse large B-cell lymphoma (DLBCL) have revealed a large number of somatic mutations and structural alterations. However, the clinical significance of these alterations is still not well defined. In this study, we have integrated the analysis of targeted next-generation sequencing of 106 genes and genomic copy number alterations (CNA) in 150 DLBCL. The clinically significant findings were validated in an independent cohort of 111 patients. Germinal center B-cell and activated B-cell DLBCL had a differential profile of mutations, altered pathogenic pathways and CNA. Mutations in genes of the NOTCH pathway and tumor suppressor genes (TP53/CDKN2A), but not individual genes, conferred an unfavorable prognosis, confirmed in the independent validation cohort. A gene expression profiling analysis showed that tumors with NOTCH pathway mutations had a significant modulation of downstream target genes, emphasizing the relevance of this pathway in DLBCL. An in silico drug discovery analysis recognized 69 (46%) cases carrying at least one genomic alteration considered a potential target of drug response according to early clinical trials or preclinical assays in DLBCL or other lymphomas. In conclusion, this study identifies relevant pathways and mutated genes in DLBCL and recognizes potential targets for new intervention strategies., This study was supported by the Ministerio de Economía y Competitividad, Grant No. SAF2015-64885- R (to EC), Generalitat de Catalunya Suport Grups de Recerca AGAUR 2014-SGR-795 (to EC), Instituto de Salud Carlos III, Spanish Ministry of Health, PI12/01536 (to AL-G) and PI16/00420 (to AL-G), the Red Temática de Investigación Cooperativa en Cáncer (RTICC) grant RD12/0036/0036 (to EC), RD12/0036/0023 (to AL-G), RD12/0036/0069 (to MA), BIO/SA78/15 (to MA) and the European Regional Development Fund 'Una manera de fer Europa', CERCA Programme/Generalitat de Catalunya. EC is an Academia Researcher of the 'Institució Catalana de Recerca i Estudis Avançats' (ICREA) of the Generalitat de Catalunya. KK has received a research fellowship from the Uehara Memorial Foundation (Japan). DT is supported by the People Programme (Marie Curie Actions) of the Seventh Framework Programme of the European Union (FP7/2007-2013) under REA grant agreement number 600388 and by the Agency of Competitiveness for Companies of the Government of Catalonia, ACCIÓ and SAF2015-74072-JIN. CR-P is supported by an FPI fellowship. ID is supported by 'Josep Font' grant from Hospital Clinic. This work was also supported by La Fundació la Marató de TV3 and EU H2020 Programme 2014-2020 under grant agreements no. 634143 (MedBioinformatics), and the European Research Council (consolidator grant 682398) (to NL-B).
UPCommons. Portal del coneixement obert de la UPC
Publicación Artículo científico (JournalArticle)

Comparison of algorithms for the detection of cancer drivers at subgene resolution

  • Porta-Pardo, Eduard
  • Kamburov, Atanas
  • Tamborero, David
  • Pons, Tirso
  • Grases, Daniela
  • Valencia, Alfonso|||0000-0002-8937-6789
  • Lopez-Bigas, Nuria
  • Getz, Gad
  • Godzik, Adam
Understanding genetic events that lead to cancer initiation and progression remains one of the biggest challenges in cancer biology. Traditionally, most algorithms for cancer-driver identification look for genes that have more mutations than expected from the average background mutation rate. However, there is now a wide variety of methods that look for nonrandom distribution of mutations within proteins as a signal for the driving role of mutations in cancer. Here we classify and review such subgene-resolution algorithms, compare their findings on four distinct cancer data sets from The Cancer Genome Atlas and discuss how predictions from these algorithms can be interpreted in the emerging paradigms that challenge the simple dichotomy between driver and passenger genes., We would like to thank the people working at The Cancer Genome Atlas for their efforts and for making all the data publicly available. E.P.-P. and A.G. acknowledge the support from the Cancer Center grants P30 CA030199 (to our institute) and R35 GM118187 (A.G.). A.K. was supported by startup funds of G.G. and by a collaboration with Bayer AG. D.T. is supported by project SAF2015- 74072-JIN, which is funded by the Agencia Estatal de Investigacion (AEI) and Fondo Europeo de Desarrollo Regional (FEDER). N.L.-B. acknowledges funding from the European Research Council (consolidator grant 682398). A.V. and T.P. acknowledge funding by the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 305444 (RD-Connect)., Peer Reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations

  • Tamborero Noguera, David
  • Rubio Pérez, Carlota, 1990-
  • Déu Pons, Jordi
  • Schroeder, Michael Philipp, 1986-
  • Vivancos Prellezo, Ana
  • Rovira Guerín, Ana
  • Tusquets Trias de Bes, Ignacio
  • Albanell Mestres, Joan
  • Rodon, Jordi
  • Tabernero Cartula, Josep
  • Torres, Carmen de
  • Dienstmann, Rodrigo
  • González-Pérez, Abel
  • López Bigas, Núria
While tumor genome sequencing has become widely available in clinical and research settings, the interpretation of tumor somatic variants remains an important bottleneck. Here we present the Cancer Genome Interpreter, a versatile platform that automates the interpretation of newly sequenced cancer genomes, annotating the potential of alterations detected in tumors to act as drivers and their possible effect on treatment response. The results are organized in different levels of evidence according to current knowledge, which we envision can support a broad range of oncology use cases. The resource is publicly available at http://www.cancergenomeinterpreter.org., This project has received funding from Fundació La Marató de TV3, the European Union's Horizon 2020 research and innovation programme 2014-2020 under grant agreement number 634143, and by the European Research Council (Consolidator Grant 682398). IRB Barcelona is a recipient of a Severo Ochoa Centre of Excellence Award from the Spanish Ministry of Economy and Competitiveness (MINECO; Government of Spain) and is supported by CERCA (Generalitat de Catalunya). DT is supported by project SAF2015-74072-JIN funded by the Agencia Estatal de Investigacion (AEI) and Fondo Europeo de Desarrollo Regional (FEDER). CR-P is funded by a FPI MINECO grant (BES-2013-063354). AG-P is supported by a Ramon y Cajal fellowship (RYC-2013-14554).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets

  • Karube, Kennosuke
  • Rubio Pérez, Carlota, 1990-
  • Tamborero Noguera, David
  • Salar, Antonio
  • Colomo Saperas, Luis Alberto
  • López Bigas, Núria
  • Miyoshi, Hiroaki
Genome studies of diffuse large B-cell lymphoma (DLBCL) have revealed a large number of somatic mutations and structural alterations. However, the clinical significance of these alterations is still not well defined. In this study, we have integrated the analysis of targeted next-generation sequencing of 106 genes and genomic copy number alterations (CNA) in 150 DLBCL. The clinically significant findings were validated in an independent cohort of 111 patients. Germinal center B-cell and activated B-cell DLBCL had a differential profile of mutations, altered pathogenic pathways and CNA. Mutations in genes of the NOTCH pathway and tumor suppressor genes (TP53/CDKN2A), but not individual genes, conferred an unfavorable prognosis, confirmed in the independent validation cohort. A gene expression profiling analysis showed that tumors with NOTCH pathway mutations had a significant modulation of downstream target genes, emphasizing the relevance of this pathway in DLBCL. An in silico drug discovery analysis recognized 69 (46%) cases carrying at least one genomic alteration considered a potential target of drug response according to early clinical trials or preclinical assays in DLBCL or other lymphomas. In conclusion, this study identifies relevant pathways and mutated genes in DLBCL and recognizes potential targets for new intervention strategies., This study was supported by the Ministerio de Economía y Competitividad, Grant No. SAF2015-64885- R (to EC), Generalitat de Catalunya Suport Grups de Recerca AGAUR 2014-SGR-795 (to EC), Instituto de Salud Carlos III, Spanish Ministry of Health, PI12/01536 (to AL-G) and PI16/00420 (to AL-G), the Red Temática de Investigación Cooperativa en Cáncer (RTICC) grant RD12/0036/0036 (to EC), RD12/0036/0023 (to AL-G), RD12/0036/0069 (to MA), BIO/SA78/15 (to MA) and the European Regional Development Fund 'Una manera de fer Europa', CERCA Programme/Generalitat de Catalunya. EC is an Academia Researcher of the 'Institució Catalana de Recerca i Estudis Avançats' (ICREA) of the Generalitat de Catalunya. KK has received a research fellowship from the Uehara Memorial Foundation (Japan). DT is supported by the People Programme (Marie Curie Actions) of the Seventh Framework Programme of the European Union (FP7/2007-2013) under REA grant agreement number 600388 and by the Agency of Competitiveness for Companies of the Government of Catalonia, ACCIÓ and SAF2015-74072-JIN. CR-P is supported by an FPI fellowship. ID is supported by 'Josep Font' grant from Hospital Clinic. This work was also supported by La Fundació la Marató de TV3 and EU H2020 Programme 2014-2020 under grant agreements no. 634143 (MedBioinformatics), and the European Research Council (consolidator grant 682398) (to NL-B).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Comparison of algorithms for the detection of cancer drivers at subgene resolution

  • Porta-Pardo, Eduard
  • Kamburov, Atanas
  • Tamborero, David
  • Pons, Tirso
  • Grases, Daniela
  • Valencia, Alfonso
  • Lopez-Bigas, Nuria
  • Getz, Gad
  • Godzik, Adam
Understanding genetic events that lead to cancer initiation and progression remains one of the biggest challenges in cancer biology. Traditionally, most algorithms for cancer-driver identification look for genes that have more mutations than expected from the average background mutation rate. However, there is now a wide variety of methods that look for nonrandom distribution of mutations within proteins as a signal for the driving role of mutations in cancer. Here we classify and review such subgene-resolution algorithms, compare their findings on four distinct cancer data sets from The Cancer Genome Atlas and discuss how predictions from these algorithms can be interpreted in the emerging paradigms that challenge the simple dichotomy between driver and passenger genes., We would like to thank the people working at The Cancer Genome Atlas for their efforts and for making all the data publicly available. E.P.-P. and A.G. acknowledge the support from the Cancer Center grants P30 CA030199 (to our institute) and R35 GM118187 (A.G.). A.K. was supported by startup funds of G.G. and by a collaboration with Bayer AG. D.T. is supported by project SAF2015- 74072-JIN, which is funded by the Agencia Estatal de Investigacion (AEI) and Fondo Europeo de Desarrollo Regional (FEDER). N.L.-B. acknowledges funding from the European Research Council (consolidator grant 682398). A.V. and T.P. acknowledge funding by the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 305444 (RD-Connect)., Peer Reviewed, Postprint (author's final draft)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Comparison of algorithms for the detection of cancer drivers at subgene resolution

  • Porta-Pardo, Eduard
  • Kamburov, Atanas
  • Tamborero Noguera, David
  • Pons, Tirso
  • Grases, Daniela
  • Valencia, Alfonso
  • López Bigas, Núria
  • Getz, Gad
  • Godzik, Adam
Understanding genetic events that lead to cancer initiation and progression remains one of the biggest challenges in cancer biology. Traditionally, most algorithms for cancer-driver identification look for genes that have more mutations than expected from the average background mutation rate. However, there is now a wide variety of methods that look for nonrandom distribution of mutations within proteins as a signal for the driving role of mutations in cancer. Here we classify and review such subgene-resolution algorithms, compare their findings on four distinct cancer data sets from The Cancer Genome Atlas and discuss how predictions from these algorithms can be interpreted in the emerging paradigms that challenge the simple dichotomy between driver and passenger genes., E.P.-P. and A.G. acknowledge the support from the Cancer Center grants P30 CA030199 (to our institute) and R35 GM118187 (A.G.). A.K. was supported by startup funds of G.G. and by a collaboration with Bayer AG. D.T. is supported by project SAF2015-74072-JIN, which is funded by the Agencia Estatal de Investigacion (AEI) and Fondo Europeo de Desarrollo Regional (FEDER). N.L.-B. acknowledges funding from the European Research Council (consolidator grant 682398). A.V. and T.P. acknowledge funding by the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 305444 (RD-Connect)
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations

  • Tamborero, David
  • Rubio-Perez, Carlota|||0000-0002-1921-168X
  • Deu-Pons, Jordi
  • Schroeder, Michael P.
  • Vivancos, Ana|||0000-0003-2888-6512
  • Rovira, Ana|||0000-0003-1301-2599
  • Tusquets, Ignasi
  • Albanell Mestres, Joan|||0000-0003-1239-4580
  • Rodón Ahnert, Jordi
  • Tabernero, Josep|||0000-0002-2495-8139
  • De Torres, Carmen
  • Dienstmann, Rodrigo|||0000-0001-5997-318X
  • Gonzalez-Perez, Abel|||0000-0002-8582-4660
  • Lopez-Bigas, Nuria|||0000-0003-4925-8988
While tumor genome sequencing has become widely available in clinical and research settings, the interpretation of tumor somatic variants remains an important bottleneck. Here we present the Cancer Genome Interpreter, a versatile platform that automates the interpretation of newly sequenced cancer genomes, annotating the potential of alterations detected in tumors to act as drivers and their possible effect on treatment response. The results are organized in different levels of evidence according to current knowledge, which we envision can support a broad range of oncology use cases. The resource is publicly available at http://www.cancergenomeinterpreter.org. The online version of this article (10.1186/s13073-018-0531-8) contains supplementary material, which is available to authorized users.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets

  • Karube, K.
  • Enjuanes, Anna|||0000-0002-4679-6687
  • Dlouhy, Iván|||0000-0003-3066-4732
  • Jares, Pedro
  • Martín-García, David|||0000-0002-0289-5915
  • Nadeu, Ferran|||0000-0003-2910-9440
  • Ordóñez, G.R.
  • Rovira, Jordi|||0000-0001-8737-5005
  • Clot, Guillem|||0000-0003-2588-7413
  • Royo, C.
  • Navarro, Alba|||0000-0002-4041-0974
  • González Farré, Blanca|||0000-0002-1796-7248
  • Vaghefi, A.
  • Castellano, Giancarlo|||0000-0002-5715-7733
  • Rubio-Perez, C.
  • Tamborero, David
  • Briones Meijide, Javier|||0000-0003-2750-3735
  • Salar Silvestre, Antonio|||0000-0002-4652-4825
  • Sancho, Juan-Manuel|||0000-0001-7168-6538
  • Mercadal, Santiago|||0000-0003-4741-7885
  • Gonzalez-Barca, E.
  • Escoda, Lourdes|||0000-0003-3288-9716
  • Miyoshi, H.
  • Ohshima, K.
  • Miyawaki, K.
  • Kato, K.
  • Akashi, K.
  • Mozos, Ana|||0000-0002-3350-1827
  • Colomo, Luis|||0000-0001-5236-5085
  • Alcoceba, Miguel|||0000-0002-3819-4846
  • Valera, A.
  • Carrió, A.
  • Costa, Dolors|||0000-0002-8276-3292
  • Lopez-Bigas, N.
  • Schmitz, R.
  • Staudt, L.M.
  • Salaverria, I.
  • López Guillermo, Armando|||0000-0002-8588-8381
  • Campo, Elias|||0000-0001-9850-9793
Genome studies of diffuse large B-cell lymphoma (DLBCL) have revealed a large number of somatic mutations and structural alterations. However, the clinical significance of these alterations is still not well defined. In this study, we have integrated the analysis of targeted next-generation sequencing of 106 genes and genomic copy number alterations (CNA) in 150 DLBCL. The clinically significant findings were validated in an independent cohort of 111 patients. Germinal center B-cell and activated B-cell DLBCL had a differential profile of mutations, altered pathogenic pathways and CNA. Mutations in genes of the NOTCH pathway and tumor suppressor genes (TP53/CDKN2A), but not individual genes, conferred an unfavorable prognosis, confirmed in the independent validation cohort. A gene expression profiling analysis showed that tumors with NOTCH pathway mutations had a significant modulation of downstream target genes, emphasizing the relevance of this pathway in DLBCL. An in silico drug discovery analysis recognized 69 (46%) cases carrying at least one genomic alteration considered a potential target of drug response according to early clinical trials or preclinical assays in DLBCL or other lymphomas. In conclusion, this study identifies relevant pathways and mutated genes in DLBCL and recognizes potential targets for new intervention strategies.